ReviewOne health (Amsterdam, Netherlands)2026
Combating antimicrobial resistance through multimodal data via artificial intelligence.
Review in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a critical global health challenge, leading to substantial mortality and economic losses without science-based interventions. Conventional approaches to combating AMR have important limitations in addressing this escalating threat. Recent advances in AI, including deep learning, large language models, and protein language models, provide new opportunities to integrate multimodal data for AMR research. However, evidence remains uneven, with many approaches limited to computational benchmarking rather than real-world validation. Here, we critically review AI applications in AMR, focusing on rapid diagnosis, therapeutic discovery, and clinical decision support. AI-based diagnostic models can identify resistant pathogens and predict resistance profiles, but most lack prospective clinical evaluation. AI-assisted drug discovery and alternative therapies have generated promising candidates, although most remain at computational, in vitro, or early preclinical stages. Large language models may support decision-making, but their clinical use remains preliminary. Successful translation of AI into clinical and One Health practice will require representative datasets, independent validation, prospective evaluation, and robust governance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.